Stock 4142 ADIMMUNE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Adimmune Corporation

Equities

4142

TW0004142005

Pharmaceuticals

End-of-day quote Taiwan S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
27.05 TWD 0.00% Intraday chart for Adimmune Corporation -1.10% -18.40%
Mar. 28 Adimmune Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Feb. 05 An unknown buyer acquire 2.14% stake in Adimmune Corporation from BioEngine Technology Development Inc. for NTD300 million. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,776 9,179 24,095 19,178 15,184 13,973
Enterprise Value (EV) 1 7,689 10,692 20,995 17,607 14,489 14,646
P/E ratio -7.85 x -28 x 18.5 x 447 x 52.4 x -21.8 x
Yield - - 0.89% - - -
Capitalization / Revenue 5.81 x 7.06 x 12.9 x 11.7 x 6.74 x 7.83 x
EV / Revenue 9.35 x 8.23 x 11.2 x 10.7 x 6.43 x 8.2 x
EV / EBITDA -16.1 x -140 x 116 x -8,997 x 44.5 x -27.7 x
EV / FCF -15.1 x -22.7 x 31.6 x -13.7 x -22.7 x -13.6 x
FCF Yield -6.64% -4.41% 3.17% -7.29% -4.41% -7.36%
Price to Book 2.93 x 2.52 x 3.81 x 3.12 x 2.45 x 2.55 x
Nbr of stocks (in thousands) 235,294 362,811 429,508 429,508 426,508 421,508
Reference price 2 20.30 25.30 56.10 44.65 35.60 33.15
Announcement Date 3/29/19 3/31/20 3/30/21 3/30/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 822.4 1,300 1,869 1,641 2,252 1,785
EBITDA 1 -478.8 -76.36 181.3 -1.957 325.8 -528
EBIT 1 -716.5 -299 -25.81 -206.8 93.57 -722.7
Operating Margin -87.13% -23% -1.38% -12.6% 4.16% -40.49%
Earnings before Tax (EBT) 1 -665.9 -314.6 1,197 14.28 156.2 -770
Net income 1 -609.1 -280.7 1,241 43.07 291 -639.9
Net margin -74.07% -21.6% 66.41% 2.62% 12.92% -35.85%
EPS 2 -2.585 -0.9043 3.030 0.1000 0.6800 -1.520
Free Cash Flow 1 -510.6 -471.1 664.6 -1,283 -638.7 -1,078
FCF margin -62.09% -36.25% 35.55% -78.17% -28.37% -60.38%
FCF Conversion (EBITDA) - - 366.62% - - -
FCF Conversion (Net income) - - 53.54% - - -
Dividend per Share - - 0.5000 - - -
Announcement Date 3/29/19 3/31/20 3/30/21 3/30/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales 1 753.3 792.8 52.8 526.9 1,087 584.6 169.7
EBITDA - - - - - - -
EBIT 1 158.2 127.3 -253.8 -34.46 353.5 28.31 -259.6
Operating Margin 21.01% 16.06% -480.68% -6.54% 32.51% 4.84% -152.96%
Earnings before Tax (EBT) 1 - - -247.1 -20.86 406.4 17.73 -269.3
Net income 1 - - -234.6 45.3 419.5 60.77 -249
Net margin - - -444.35% 8.6% 38.58% 10.39% -146.73%
EPS 2 - - -0.5500 0.1100 0.9800 0.1400 -0.5900
Dividend per Share - - - - - - -
Announcement Date 11/12/21 3/30/22 5/16/22 8/15/22 11/14/22 3/30/23 5/15/23
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 2,912 1,513 - - - 673
Net Cash position 1 - - 3,101 1,570 695 -
Leverage (Debt/EBITDA) -6.083 x -19.82 x - - - -1.274 x
Free Cash Flow 1 -511 -471 665 -1,283 -639 -1,078
ROE (net income / shareholders' equity) -31.7% -11.1% 22.9% 0.22% 2.25% -12.5%
ROA (Net income/ Total Assets) -7.84% -3.05% -0.21% -1.57% 0.68% -4.85%
Assets 1 7,770 9,199 -578,939 -2,746 42,690 13,198
Book Value Per Share 2 6.920 10.00 14.70 14.30 14.50 13.00
Cash Flow per Share 2 2.640 2.900 9.520 6.170 6.780 5.830
Capex 1 44.2 251 537 844 419 378
Capex / Sales 5.37% 19.29% 28.73% 51.44% 18.63% 21.16%
Announcement Date 3/29/19 3/31/20 3/30/21 3/30/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
ADIMMUNE CORPORATION Stock Adimmune Corporation
-18.40% 350M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4142 Stock
  4. Financials Adimmune Corporation